Ewing's sarcoma

✍ Scribed by Rajaram S. Iyer; S. R. Rao; A. Gurjal; Chandrika N. Nair; Suresh K. Pai; Purna A. Kurkure; Subodh C. Pande; Dr. Suresh H. Advani

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: English
• Weight: 424 KB
• Volume: 52
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930520315

✦ Synopsis

Between 1984Between -1987, 50 , 50

patients with Ewing's sarcoma of the bone were entered on combined modality protocol at Tata Memorial Hospital. Protocol treatment involved induction therapy consisting of 6-week therapy with vincristine, Adriamycin (doxorubicin), and cyclophosphamide (VDC) followed by local radiotherapy 50 Gy to the involved bone. This was followed for six more cycles of VDC. Five patients had metastatic disease at presentation. Seventy-six percent (38/50) of patients had disease either at axial or proximal site. With a median follow-up of 48 months (range 14-87) 21 patients remained alive with disease-free survival of 38.0% * 2.5% at 5 years and overall survival of 36.0% ? 2.6% at 5 years. Twentyfive patients relapsed with five patients developing local failure and four local and distant metastasis. Using Lee-Desu statistical methods, only response to therapy was a significant factor for survival. We conclude that more aggressive therapy with proper selection of local treatment modality including surgery and/or radiotherapy is required to produce more longterm survival in high-risk Ewing's sarcoma.